1774 studies found for:    EGFR
Show Display Options
Rank Status Study
1 Active, not recruiting Asia Pacific and Russia Diagnostic Study for EGFR Testing
Condition: EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Intervention: Genetic: EGFR mutation test
2 Unknown  Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment
Condition: NSCLC
Intervention: Other: cancer cell lines establishment
3 Recruiting Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
Condition: Advanced EGFR-positive Solid Tumors
Intervention: Biological: CART-EGFR
4 Recruiting CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
Condition: Advanced Glioma
Intervention: Biological: anti-EGFR CAR T
5 Recruiting Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
Condition: Carcinoma, Squamous Cell
Intervention: Biological: EGFR Antisense DNA
6 Recruiting Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
Conditions: Non-Small Cell Lung Cancer;   Brain Metastases;   EGFR Gene Mutation
Interventions: Drug: Gefitinib;   Radiation: WBRT
7 Completed Anti-EGFR Immunoliposomes in Solid Tumors
Condition: Solid Tumors
Intervention: Drug: anti-EGFR immunoliposomes loaded with doxorubicin
8 Recruiting Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Condition: EGFR Mutation Positive Non-small Cell Lung Cancer
Intervention: Drug: EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
9 Completed Europe-Japan Diagnostic Study for EGFR Testing
Condition: EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Intervention:
10 Completed Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)
Condition: NSCLC Non Small Cells Lung Cancer
Intervention:
11 Completed Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis
Conditions: Gastroesophageal Reflux Disease;   Chronic Laryngitis
Interventions: Procedure: Biopsy of the retrocrycoid laryngeal mucosa;   Procedure: Biopsy of the distal esophageal mucosa
12 Active, not recruiting Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
Conditions: Squamous Cell Carcinoma;   Head and Neck Cancer
Intervention: Biological: EGFR Antisense DNA
13 Completed Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
14 Recruiting A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
Condition: EGFR Positive Solid Tumors
Intervention: Drug: IMGN289
15 Recruiting Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
Condition: Advanced Stage Non Small Cell Lung Cancer
Interventions: Drug: Erlotinib 100mg qd;   Drug: Gefitinib 250mg qd
16 Not yet recruiting Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
Condition: Asymptomatic Brain Metastases of Non Small Cell Lung Cancer
Intervention: Drug: EGFR-TKI
17 Unknown  Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
Condition: Metastatic Non-Small-Cell Lung Cancer
Intervention:
18 Active, not recruiting Detecting EGFR T790M Mutations From Circulating Tumor Cells
Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
19 Active, not recruiting Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
Condition: EGFR Inhibitor-associated Rash
Intervention: Drug: Menadione Topical Lotion
20 Recruiting Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
Conditions: NSCLC;   EGFR Mutation
Intervention: Drug: Erlotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years